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A B S T R A C T
A well-characterized standardized hydroethanolic extract of a traditionally recognized mak (mild) variety
of Sceletium tortuosum, a South African plant with a long history of traditional ingestion, is marketed under
the trade name Zembrin® as an ingredient for use in functional foods and dietary supplements. It is stan-
dardized to contain 0.35–0.45% total alkaloids (mesembrenone and mesembrenol ≥60%, and mesembrine
<20%). A 14-day repeated oral toxicity study was conducted at 0, 250, 750, 2500, and 5000 mg/kg bw/
day. A 90-day subchronic repeated oral toxicity study was conducted at 0, 100, 300, 450, and 600 mg/kg
bw/day. Because S. tortuosum has a long history of human use for relieving stress and calming, a func-
tional observation battery, including spontaneous locomotor activity measured using LabMaster ActiMot
light-beam frames system, was employed. Several parameters, such as locomotion, rearing behavior, spatial
parameters, and turning behavior were investigated in the ﬁnal week of the study. No mortality or
treatment-related adverse effects were observed in male or female Crl:(WI)BR Wistar rats in the 14- or
90-day studies. In the 14- and 90-day studies, the NOAELs were concluded as 5000 and 600 mg/kg bw/
d, respectively, the highest dose groups tested.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The endemic South African succulent plant Sceletium tortuosum
(L.) N.E. Br. has an ancient oral history of use as a masticatory prep-
aration and health tea by indigenous San and Khoi people. The ﬁrst
written record of the plant being used by indigenous people, ac-
companied by a painting of the plant, is from the year 1685
(Waterhouse et al., 1979). Tinctures (hydroethanolic extracts) of the
plant were reported to be in common use by colonists of the Cape
of Good Hope (Pappe, 1868) and can still be purchased from health
shops, pharmacies, and farm stalls in South Africa. Packages of
S. tortuosum tea bags, often in combination with Red Bush Tea
(Aspalathus linearis) or Honeybush tea (Cyclopia spp.), are sold in su-
permarkets in South Africa. Over the last 15 years, increasing
numbers of Sceletium-based products, including teas, tinctures,
tablets, capsules, and raw powdered plant material, often sold over
the Internet, are being used by healthy individuals to promote a sense
of well-being and to relieve stress (Gericke and Viljoen, 2008).
There has been considerable research on the chemistry of the
alkaloids contained in the plant (Gericke and Viljoen, 2008). A wide
range of variation of the alkaloid chemistry in wild Sceletium plants
has been described (Shikanga et al., 2012), indicating the necessi-
ty of selecting naturally occurring and traditionally used plant
chemotypes for commercial production and standardizing ex-
tracts of these plants to both the total alkaloid content and the
alkaloid composition in order to have high quality commercial prod-
ucts. The four major S. tortuosum alkaloids (mesembrine,
mesembrenone, mesembrenol, andmesembranol) have been shown
in vitro to be permeable across porcine intestinal, sublingual, and
buccal mucosa (Shikanga et al., 2012).
No formal toxicological studies have been previously pub-
lished on S. tortuosum or on extracts of S. tortuosum. Small-scale
short-term studies in dogs and cats have been reported (Hirabayashi
et al., 2002, 2004) with no adverse effects noted after daily admin-
istration of dried S. tortuosum plant material for 6 or 7 days.
The safety and tolerability of two doses (8 mg and 25 mg once
daily) of S. tortuosum extract (Zembrin®) (equivalent to 16 mg and
50mg dry plant material, respectively) was studied over a 3-month
period in a randomized double-blind placebo-controlled parallel-
Abbreviations: HPLC-DAD, high-performance liquid chromatography-diode array
detector; SPF, speciﬁc pathogen-free.
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group study (n = 37) (Nell et al., 2013). The safety and tolerability
variables studiedwere vital signs, physical examination, 12-lead elec-
trocardiogram, laboratory assessments (hematology, biochemistry,
and urinalysis), and the recording of adverse events (AEs). Therewere
no apparent differences in any of the safety and tolerability param-
eters studied, and both doses of the extract were well-tolerated.
Historical use and emerging preclinical and clinical evidence
suggest that there is potential for the standardized extract of
S. tortuosum – Zembrin® – to be used in teas and as a dietary sup-
plement to enhance and/or maintain health and wellness in healthy
people wanting to feel calmer and under less stress.
As a prelude to further development, the safety of Zembrin®, a
well-characterized (see Table 1) extract of S. tortuosum standard-
ized to contain 0.35–0.45% total alkaloids (mesembrenone and
mesembrenol ≥60%, and mesembrine <20%), has been formally
studied in vivo in 14-day and 90-day repeated oral toxicity studies
in rats, reported here for the ﬁrst time.
2. Materialss and methods
2.1. Test article
The test article was Zembrin® (manufactured by Polifenoles Naturales, SL, Pol.
Ind. Las Majoreras, 35240 Ingenio, Las Palmas, Spain for HG&H Pharmaceuticals (Pty)
Ltd., The Braes, 193 Bryanston Drive, Bryanston 2191, South Africa), a proprietary
standardized 2:1 hydroethanolic extract of the dried leaves and stems of S. tortuosum.
Zembrin® was provided for use as the test article (batch numbers SCE0411-1605
and SCE0412-0901 for the 14- and 90-day studies, respectively), along with speci-
ﬁcations, certiﬁcates of analysis, and material safety data sheets, by HG&H
Pharmaceuticals (Pty) Ltd. A brief description of Zembrin® and its manufacturing
process is provided as follows:
As declared by HG&H Pharmaceuticals (Pty) Ltd, the source plant material was
cultivated in South Africa. No phytochemicals were used during the production of
S. tortuosum rawmaterial for the production of Zembrin® and nonewere added during
the manufacturing process. The production farms where the S. tortuosum source ma-
terial for Zembrin® was grown are Global Good Agricultural Practice (GAP) certiﬁed.
The use of pesticides in the cultivation of the S. tortuosum sourcematerial for Zembrin®
was limited and restricted to the period of seed germination. During growth and
after drying, samples of the harvested and dried plant source material were sent
to internationally certiﬁed analytical laboratories to ensure conformity with inter-
national standards for pesticide residues, heavy metals, aﬂatoxins, and microbiology
and exclusion of pathogenic bacteria, and the plant identity was conﬁrmed by mac-
roscopic characteristics, qualitative (GC-MS), and quantitative (HPLC) methods.
The above ground parts were harvested, washed, and air-dried before sending
to Polifenoles Naturales, SL (an EU-GMP certiﬁed manufacturer of plant extract) for
extraction. The dried material was milled, extracted with water–ethanol (puriﬁed
water 30% v/v and ethanol 70% v/v), ﬁltered, distilled to remove residual solvent,
and concentrated before spray drying onto a maltodextrin carrier that was ad-
justed to produce the speciﬁed standardization of alkaloids. After the extraction,
concentration, and standardization processes, each lot (batch) of Zembrin® was tested
for total alkaloid content, alkaloid composition, pesticide residues, heavy metals, af-
latoxins, andmicrobiology to ensure compliance with ﬁnished product speciﬁcations.
The ﬁnal product – Zembrin® – is a food-grade, non-GMO, certiﬁed allergen-
free and BSE (contains no animal derivatives) free product that is fully soluble
in water and is standardized to an alkaloid content of 0.35–0.45% w/w
(HPLC-DAD). The relative amounts of major alkaloids (HPLC-DAD) are:
mesembrenone + mesembrenol ≥ 60% and mesembrine <20%. Fig. 1 shows the
chemical structures of the four active alkaloids.
Multiple compositional analyses have identiﬁed the major constituents
of Zembrin® to be carbohydrates, ash, protein, and fatty acids. Minor constituents
include alkaloids andminerals. The typical compositional analysis is shown in Table 1
above.
2.2. Studies
The GLP animal studies reported below were conducted in compliance with in-
ternationally accepted guidelines: OECD 407 (14-day study) (OECD, 2008) and OECD
408 (90-day study) (OECD, 1998) and US FDA Redbook 2000, IV.C.3.a (14-day study)
(FDA, 2003a) and IV.C.4.a (90-day study) (FDA, 2003b). Care and use of study animals
was in accordance with the National Research Council Guide for Care and Use of
Laboratory Animals (NRC, 2011) and in compliance with the principles of the Hun-
garian Act 2011 CLVIII (modiﬁcation of Hungarian Act 1998 XXVIII) regulating animal
protection.
Distilled water for parenteral administration was used as the control and the
vehicle for administration of the test article. The test article doses were prepared
by dissolving Zembrin® in distilled water to achieve concentrations of 25, 75, 250,
and 500mg/mL (14-day study) and 10, 30, 45, and 60mg/mL (90-day study) to provide
a constant dosing volume of 10mL/kg bw. Doses were prepared daily, shortly before
administration, during the 14-day study and either daily or within 7 days of ad-
ministration during the 90-day study due to results of stability analysis indicating
that Zembrin® is stable when dissolved in distilled water over a 10 day interval. The
control group received the same volume of the vehicle only. The concentration, sta-
bility, and alkaloid concentration and composition of the dosing solutions was
independently veriﬁed analytically prior to beginning the 14-day study, and con-
centrations of the dosing solutions were independently veriﬁed analytically twice
during the 14-day study and three times during the 90-day study. Analysis of the
test article was performed in a non-GLP academic analytical laboratory experi-
enced in chromatographic quantitative analysis of mesembrine-alkaloids using
validated analytical reference compounds.
Speciﬁc pathogen-free (SPF) male and female Crl:(WI)BR Wistar rats (Toxi-
Coop, Budapest, Hungary) were utilized in both studies. The animals were housed
in individual type II polypropylene/polycarbonate cages with certiﬁed laboratory wood
bedding (Lignocel®) (cages and bedding were changed once a week), at 22 ± 3 °C,
30–70% relative humidity, and a 12-hour light-dark cycle. The animals received ssniff®
SM R/M-Z + H complete diet for rats and mice and potable tap water ad libitum. The
health status of the animals was certiﬁed by the breeder, and a pre-experimental
period (12-days, 14-day study/15-days, 90-day study) was provided to acclimatize
the animals.
2.2.1. Fourteen-day repeated-dose oral toxicity study in rats
This dose range-ﬁnding study was carried out in order to evaluate repeated oral
administration, over a 14-day period, of the test article in male and female rats for
a broad range of doses in order to determine a no observed adverse effect level
(NOAEL) and to provide data for the selection of the dose groups for the 90-day re-
peated oral toxicity study.
Fifty male and female SPF Wistar rats, approximately 7 weeks old and weigh-
ing 231–255 g (males) and 168–204 g (females) at the start of the experimental period,
were stratiﬁed by weight and randomly assigned to ﬁve groups of ﬁve rats/sex/
group for administration of Zembrin® doses of 0 (vehicle-control), 250, 750, 2500,
and 5000 mg/kg bw/day by gavage for 14-days.
The animals were observed twice daily for mortality. General cage-side obser-
vations for clinical signs were made twice during the acclimation period and once
daily after administration of the test article, and detailed clinical observations were
Table 1
Compositional analysis of Sceletium tortuosum extract (Zembrin®).a
Analysis Result (% dry weight)
Moisture 6.01
Carbohydrates 52.23
Protein (nitrogen X 6.25) 6.49
Fatty acids 3.84
Alkaloids 0.417
Total minerals (ash content) 33.3
TOTAL 102.3b
Individual mineral analysis Result (% dry weight)
Iron 0.015
Calcium 0.033
Sodium 2.71
Total oxalates 12.9
Silicon dioxide ≤2
Heavy metals total ≤10 ppm
Abbreviations: ppm, parts per million.
a Analyses based on internal methods.
b Table results are the mean values reported from four separate and indepen-
dent analyses of the various constituents.
Fig. 1. Structures of the four main mesembrine alkaloids that are quantiﬁed by HPLC
to deﬁne the alkaloid content and composition of the extract of Sceletium tortuosum
(Zembrin®).
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conducted twice weekly. Measurements of food intake and body weight were
conducted twice during the acclimation period and twice weekly during the ex-
perimental period; body weights were also determined immediately prior to sacriﬁce.
Ophthalmological examination was carried out prior to and at the end of the ex-
perimental period.
After an overnight fast (approximately 16 hours) following ﬁnal administra-
tion of the test article, blood samples were collected from the retro orbital venous
plexus under Isoﬂuran CP® anesthesia after which the animals were euthanized by
exsanguination from the abdominal aorta. Blood samples were analyzed for hema-
tologic and clinical chemistry parameters and gross pathological examinations and
determinations of selected organ weights (absolute and relative) were conducted
on all animals. Full histopathological examinations were conducted on the pre-
served organs and tissues of all animals of the control and high-dose groups.
Histopathological examinations of kidneys, from some animals of the low- andmiddle-
dose groups, in which lesions were observed on gross examination, were also
conducted.
2.2.2. Ninety-day repeated-dose oral toxicity study in rats
The study was conducted in order to evaluate the possible health hazards, in-
cluding identiﬁcation of toxic effects and target organs, of repeated oral exposure
to Zembrin® inmale and female rats over a 90-day period and to determine the NOAEL.
One hundred SPF male and female Wistar rats, approximately 8 weeks old and
weighing 264–316 g (males) and 171–220 g (females) at the start of the experi-
mental period, were stratiﬁed by weight and randomly assigned to ﬁve groups of
10 rats/sex/group for administration of Zembrin® doses of 0 (vehicle-control), 100,
300, 450, and 600 mg/kg bw/day by gavage for 90-days. Dose selection was based
on the previous results of the 14-day study with the lowest and highest doses cor-
responding to approximately 300- and 1800-fold, respectively, the proposed human
use level of 25 mg daily (357 μg/kg in a 70 kg adult).
The animals were observed twice daily for mortality. General cage-side obser-
vations for clinical signs were performed once daily after administration of the test
article, and detailed clinical observations were performed 1 day prior to the ﬁrst
treatment andweekly thereafter. Measurements of bodyweight were conducted twice
during the acclimation period, on the ﬁrst experimental day prior to treatment, twice
weekly during weeks 1–4, once a week during weeks 5–13, and immediately prior
to sacriﬁce. Food intake was determined and food eﬃciency calculated once weekly.
Ophthalmological examination was carried out on all animals prior to, and on control
and high-dose animals at the end of, the experimental period.
A functional observation battery performed during the ﬁnal week assessed tests
for general physical condition and behavior, sensory reactivity to stimuli, grip strength,
and locomotor activity. Spontaneous locomotor activity was further assessed on one
occasion during the ﬁnal week using a LabMaster ActiMot light-beam frames system.
The X, Y, and Z axis infrared (IR) sensor arrays of the ActiMot light-beam frames
systemmonitored the activity of the animals in a 54 × 29 × 41 cm cage inserted inside
the sensory frame. In the cage positioned into the frame, the X-axis represented length
(54 cm), the Y-axis represented depth (29 cm), and the Z-axis represented height
(41 cm). Within the ActiMot system frame, movement along the X-axis was moni-
tored by 16 sensors (emitter and receiver pairs) installed along the long sides (54 cm)
and movement along the Y-axis was monitored by eight sensors installed along the
short sides (29 cm), respectively, of one ﬂat frame. Movement along the Z-axis was
monitored by 16 sensors installed along the long sides (54 cm) of a second ﬂat frame
parallel to and above the X/Y ﬂat frame (i.e., the Z-axis sensor array was parallel to
the X-axis sensor array and no sensors were installed in the short sides of the “Z
level” frame). The position of the ﬂat frame containing the “Z level” sensor array
was vertically adjustable along the Z-axis by sliding up and down the four vertical
corner frame posts of the system. The X- and Y-axis sensor arrays jointly moni-
tored horizontal activity/movement, the Z-axis sensor arraymonitored vertical activity/
movement, and computer software algorithms translated spatial temporal beam
interruption patterns into animal activity patterns representing the evaluated
parameters.
Animals were examined individually, outside of their home cage environ-
ments, in the absence of any disturbing circumstances. The evaluated parameters
were locomotion and activity (time resting in seconds, time moving in seconds, time
hyperactive in seconds, distance travelled in meters, locomotor speed in cm/s, and
overall speed in cm/s occurring in the central and peripheral areas and both areas
combined), rearing behavior (time in rearing in seconds and the number of rearings
in the center and peripheral areas; total rearing and time in rearing in seconds in
both areas; and rearing time in seconds in corners 1, 2, 3, and 4 of the system), and
turning behavior (both clockwise and counterclockwise in the central and periph-
eral areas and both areas combined).
After an overnight fast (approximately 16 hours) following ﬁnal administra-
tion of the test article, blood samples were collected from the retro orbital venous
plexus under Isoﬂuran CP® anesthesia after which the animals were euthanized by
exsanguination from the abdominal aorta. Blood samples were analyzed for hema-
tologic and clinical chemistry parameters, and gross pathological examinations and
determinations of selected organ weights (absolute and relative) were conducted
on all animals. Histopathological examinations were conducted on the preserved
organs and tissues of all animals of the control and high-dose groups and on gross
lesions observed in animals of the lower dose groups.
2.3. Statistical analyses
Statistical analyses were conducted using SPSS PC+ software, version 4 (SPSS,
Inc., Chicago, IL). Bartlett’s homogeneity of variance test was used to assess heter-
ogeneity of variance between groups. A one-way analysis of variance (ANOVA) was
conducted where no signiﬁcant heterogeneity was detected followed by Duncan’s
Multiple Range test to assess the signiﬁcance of inter-group differences if a posi-
tive ANOVA result was obtained. Kolmogorov–Smirnov test was performed to examine
Table 2
Summary of mean body weight and mean food intake data in the 14-day repeated oral toxicity study.
Mean body weight (g) Initial (Day 0) Midway (Day 7) End (Day 13)
Male
Control (N = 5) 244.6 ± 6.5 289.6 ± 6.8 316.2 ± 9.5
250 mg/kg bw/day (N = 5) 247.0 ± 5.6 295.4 ± 10.8 327.8 ± 17.5
750 mg/kg bw/day (N = 5) 245.0 ± 8.6 291.0 ± 15.3 320.8 ± 17.7
2500 mg/kg bw/day (N = 5) 244.4 ± 8.4 292.0 ± 16.0 319.2 ± 14.5
5000 mg/kg bw/day (N = 5) 244.8 ± 10.2 287.2 ± 18.4 316.4 ± 24.8
Female
Control (N = 5) 183.6 ± 9.5 202.6 ± 9.7 213.6 ± 13.0
250 mg/kg bw/day (N = 5) 188.4 ± 10.9 211.8 ± 24.3 232.2 ± 26.5
750 mg/kg bw/day (N = 5) 185.4 ± 11.0 208.4 ± 11.0 222.0 ± 15.2
2500 mg/kg bw/day (N = 5) 183.0 ± 11.0 205.6 ± 14.7 224.6 ± 19.5
5000 mg/kg bw/day (N = 5) 181.4 ± 6.9 208.6 ± 4.5 225.6 ± 5.9
Mean food consumption (g/rat/day) Days 0–3 Days 3–7 Days 7–10 Days 10–13
Male
Control (N = 5) 25.4 ± 1.4 26.5 ± 1.2 26.7 ± 1.2 27.9 ± 0.6
250 mg/kg bw/day (N = 5) (% Deviation from control) 26.1 ± 1.5 (3) 27.5 ± 2.4 (4) 25.6 ± 1.7 (−4) 28.3 ± 1.7 (2)
750 mg/kg bw/day (N = 5) (% Deviation from control) 25.7 ± 1.7 (1) 27.0 ± 1.3 (2) 24.7 ± 2.2 (−8) 27.2 ± 1.6 (−2)
2500 mg/kg bw/day (N = 5) (% Deviation from control) 25.1 ± 1.4 (−1) 26.2 ± 1.6 (−1) 25.1 ± 2.2 (−6) 27.2 ± 1.3 (−2)
5000 mg/kg bw/day (N = 5) (% Deviation from control) 23.4 ± 3.1 (−8) 25.6 ± 2.8 (−3) 24.0 ± 2.7 (−10) 26.6 ± 2.8 (−5)
Female
Control (N = 5) 18.3 ± 1.4 18.8 ± 1.0 17.9 ± 0.5 19.8 ± 1.3
250 mg/kg bw/day (N = 5) (% Deviation from control) 19.7 ± 3.3 (8) 21.0 ± 4.5 (11) 19.9 ± 4.9 (11) 21.5 ± 2.9 (8)
750 mg/kg bw/day (N = 5) (% Deviation from control) 20.2 ± 3.5 (10) 19.9 ± 1.0 (6) 18.3 ± 1.0 (2) 20.8 ± 1.6 (5)
2500 mg/kg bw/day (N = 5) (% Deviation from control) 23.3 ± 1.4 (27) 19.5 ± 2.1 (4) 18.1 ± 2.4 (1) 21.3 ± 2.4 (8)
5000 mg/kg bw/day (N = 5) (% Deviation from control) 22.5 ± 0.4 (23) 20.9 ± 1.5 (11) 18.3 ± 1.7 (2) 21.9 ± 2.9 (11)
Mean body weight data represent the mean and the standard deviation at the beginning, mid-way through, and end of the study.
Food intake data represent the mean value per rat per day and percent deviation from control at the beginning, mid-way through, and end of the study.
Statistical signiﬁcance was set at P < 0.05.
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Table 3
Summary of hematological ﬁndings in the 14-day repeated oral toxicity study.
Group (N = 5)
(mg/kg bw/day)
WBC (109/L) NEU (%) LYM (%) MONO (%) EOS (%) BASO (%) RBC (1012/L) HGB (g/L) HCT (L/L) MCV (fL) MCH (pg) MCHC (g/L) PLT (109/L) RET (%)
Male
Control 8.5 ± 0.7 12.0 ± 1.8 83.9 ± 2.4 2.9 ± 0.9 1.1 ± 0.2 0.1 ± 0.0 8.3 ± 0.2 161.0 ± 8.9 0.4 ± 0.0 53.9 ± 2.2 19.3 ± 0.6 357.8 ± 3.3 980.6 ± 70.8 3.6 ± 0.3
250 8.1 ± 1.1 15.1 ± 4.2 80.0 ± 4.4 3.1 ± 0.8 1.7 ± 0.4 0.1 ± 0.0 8.0 ± 0.4 132.2 ± 50.6 0.4 ± 0.0 54.0 ± 2.0 19.1 ± 0.7 371.4 ± 37.8 823.0 ± 376.9 4.1 ± 0.5
750 8.2 ± 1.4 13.0 ± 1.3 82.1 ± 2.6 3.1 ± 0.6 1.7 ± 1.0 0.1 ± 0.1 7.8 ± 0.7 156.0 ± 8.6 0.4 ± 0.0 56.6 ± 3.7 19.9 ± 1.0 353.0 ± 6.4 959.2 ± 185.9 4.0 ± 0.2
2500 10.7 ± 1.2** 13.6 ± 1.6 81.2 ± 2.0 3.8 ± 0.6 1.3 ± 0.5 0.1 ± 0.0 7.9 ± 0.3 156.8 ± 1.1 0.4 ± 0.0 56.8 ± 1.7 20.0 ± 0.6 351.4 ± 5.3 874.4 ± 35.2* 3.8 ± 0.5
5000 11.1 ± 3.3 19.8 ± 5.0** 75.4 ± 5.5** 3.5 ± 1.6 1.2 ± 0.2 0.1 ± 0.0 8.1 ± 0.2 185.2 ± 7.2 0.4 ± 0.0 55.6 ± 1.6 19.6 ± 0.7 352.2 ± 2.2* 1142.2 ± 159.0 4.3 ± 1.0
Female
Control 7.7 ± 1.1 9.4 ± 2.7 86.2 ± 4.7 3.1 ± 2.0 1.3 ± 0.8 0.1 ± 0.1 8.6 ± 0.4 169.4 ± 4.7 0.5 ± 0.0 54.4 ± 2.1 19.7 ± 0.7 362.6 ± 3.8 948.6 ± 113.6 3.1 ± 0.6
250 7.8 ± 0.8 11.5 ± 2.7 84.8 ± 2.7 2.3 ± 0.6 1.3 ± 0.7 0.1 ± 0.0 8.3 ± 0.2 156.4 ± 3.8** 0.4 ± 0.0** 53.1 ± 2.3 18.9 ± 0.7 356.2 ± 4.7 989.0 ± 99.1 3.7 ± 0.4
750 7.7 ± 1.7 11.3 ± 3.8 84.3 ± 4.4 2.5 ± 0.4 1.9 ± 0.9 0.0 ± 0.1 8.6 ± 0.4 164.0 ± 3.5 0.5 ± 0.0 53.2 ± 2.1 19.1 ± 0.6 359.4 ± 5.5 952.0 ± 69.0 3.0 ± 0.7
2500 6.5 ± 1.0 10.6 ± 1.6 85.6 ± 1.6 2.3 ± 0.9 1.3 ± 0.2 0.2 ± 0.1 8.0 ± 0.2* 155.2 ± 3.6** 0.4 ± 0.0** 54.3 ± 2.7 19.4 ± 0.6 357.2 ± 8.8 1067.0 ± 170.2 4.0 ± 0.7*
5000 6.8 ± 1.2 11.6 ± 2.3 84.3 ± 2.3 2.6 ± 0.8 1.4 ± 0.4 0.1 ± 0.1 8.0 ± 0.4* 156.8 ± 4.7** 0.4 ± 0.0** 55.6 ± 2.3 19.7 ± 0.7 354.4 ± 4.0 1032.6 ± 141.2 3.8 ± 0.4
Abbreviations: WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; MONO, monocyte; EOS, eosinophil; BASO, basophil; RBC, red blood cell; HBG, hemoglobin; HTC, hematocrit; MCV, mean corpuscular volume; MCH,
mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelet; RET, reticulocyte.
Data represent the mean values and the standard deviation.
*P < 0.05 and **P < 0.01.
Table 4
Summary of clinical chemistry in the 14-day repeated oral toxicity study.
Group
(N = 5)
(mg/kg
bw/day)
ALT
(U/L)
AST
(U/L)
GGT
(U/L)
ALP
(U/L)
Bilirubin
(μmol/L)
Creatinine
(μmol/L)
Urea
(mmol/L)
Glucose
(mmol/L)
Cholesterol
(mmol/L)
Bile acids
(μmol/L)
Phosphate
(mmol/L)
Calcium
(mmol/L)
Sodium
(mmol/L)
Potassium
(mmol/L)
Chloride
(mmol/L)
Protein
(g/L)
Albumin
(g/L)
A/G
Ratio
Male
Control 44.7 ± 3.5 112.7 ± 10.6 – 162.6 ± 20.6 1.9 ± 0.2 20.2 ± 2.7 5.1 ± 0.5 6.1 ± 0.8 2.1 ± 0.2 50.8 ± 27.8 2.7 ± 0.2 2.7 ± 0.1 139.2 ± 0.8 4.1 ± 0.2 98.2 ± 1.4 58.5 ± 0.8 32.7 ± 0.7 1.3 ± 0.1
250 43.8 ± 5.3 100.5 ± 11.5 – 187.2 ± 28.1 1.9 ± 0.2 19.7 ± 1.8 5.2 ± 1.1 5.7 ± 0.5 2.2 ± 0.3 45.9 ± 16.2 2.8 ± 0.2 2.8 ± 0.1 139.6 ± 0.5 4.3 ± 0.1 99.8 ± 1.4 57.5 ± 0.6 32.5 ± 0.2 1.3 ± 0.0
750 48.1 ± 3.7 106.2 ± 9.3 – 179.8 ± 30.9 1.9 ± 0.2 20.3 ± 1.9 4.9 ± 0.9 5.8 ± 0.7 2.0 ± 0.2 42.1 ± 14.2 2.9 ± 0.3 2.7 ± 0.1 139.0 ± 0.0 4.1 ± 0.1 98.9 ± 0.5 57.7 ± 2.2 32.1 ± 0.8 1.3 ± 0.1
2500 54.1 ± 5.5* 109.3 ± 8.2 – 181.6 ± 32.8 1.8 ± 0.3 18.4 ± 1.6 5.8 ± 0.7 5.8 ± 0.4 2.4 ± 0.5 42.0 ± 14.9 3.1 ± 0.1* 2.8 ± 0.1 138.8 ± 0.8 4.2 ± 0.1 98.3 ± 0.8 58.4 ± 2.8 32.7 ± 0.8 1.3 ± 0.1
5000 49.4 ± 9.6 91.3 ± 5.4** – 159.6 ± 8.1 1.7 ± 0.3 19.8 ± 2.5 7.6 ± 2.5** 5.7 ± 0.6 2.0 ± 0.1 56.2 ± 42.3 3.4 ± 0.3** 2.8 ± 0.1*,a 137.8 ± 1.1* 4.1 ± 0.2 96.8 ± 2.3 55.2 ± 2.2* 31.2 ± 0.9** 1.3 ± 0.2
Female
Control 42.4 ± 9.6 96.6 ± 10.5 – 103.6 ± 19.2 2.4 ± 0.4 22.4 ± 1.2 5.4 ± 0.6 6.6 ± 0.5 2.2 ± 0.3 27.8 ± 6.6 2.7 ± 0.3 2.7 ± 0.0 141.6 ± 0.5 3.9 ± 0.1 100.1 ± 1.2 58.8 ± 1.8 33.7 ± 1.2 1.3 ± 0.1
250 44.4 ± 10.8 101.6 ± 11.4 – 113.8 ± 23.4 2.0 ± 0.4 23.9 ± 2.6 6.3 ± 0.7 6.3 ± 0.6 2.1 ± 0.2 38.1 ± 29.6 2.5 ± 0.3 2.7 ± 0.1 141.8 ± 1.6 3.9 ± 0.3 99.9 ± 2.6 55.4 ± 1.8 32.1 ± 1.3 1.4 ± 0.1
750 43.6 ± 11.6 103.2 ± 29.1 – 126.6 ± 30.7 2.3 ± 0.6 23.1 ± 2.6 6.7 ± 1.4 5.9 ± 0.2 1.8 ± 0.3 36.6 ± 14.6 2.5 ± 0.2 2.8 ± 0.1 141.2 ± 0.8 4.1 ± 0.3 99.9 ± 0.9 57.9 ± 2.0 33.5 ± 0.9 1.4 ± 0.1
2500 48.8 ± 6.7 99.1 ± 11.5 – 110.8 ± 18.5 1.9 ± 0.2* 22.0 ± 1.6 5.8 ± 0.6 6.3 ± 0.7 1.8 ± 0.4 55.0 ± 37.5 2.5 ± 0.1 2.7 ± 0.1 141.8 ± 1.1 4.1 ± .02 100.2 ± 1.7 57.6 ± 1.4 33.0 ± 1.0 1.3 ± 0.1
5000 45.2 ± 15.3 91.1 ± 9.9 – 125.6 ± 22.8 1.7 ± 0.1** 21.0 ± 2.0 6.7 ± 1.8 5.9 ± 0.7 2.1 ± 0.2 56.8 ± 37.5 2.6 ± 0.1 2.7 ± 0.1 141.4 ± 2.1 3.9 ± 0.3 99.1 ± 3.3 55.4 ± 2.9* 31.7 ± 1.4* 1.3 ± 0.1
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; A/G, albumin to globulin ratio; –, below quantitation limit (7 U/L).
Data represent the mean values and the standard deviation.
*P < 0.05 and **P < 0.01.
a Apparence of similarity to non-signiﬁcant results due to rounding.
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the distribution of data where signiﬁcant heterogeneity was detected by Bartlett’s
test, and Kruskal–Wallis non-parametric one-way ANOVA, followed by the Mann–
Whitney U-test for inter-group comparisons of positive results, was used in the case
of a non-normal distribution. A P-value of <0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Fourteen-day repeated oral toxicity study in rats
No mortality was observed in any of the dose groups during the
14-day treatment period. The animals exhibited normal behavior
and physical condition with no signiﬁcant abnormalities in clini-
cal signs observed throughout the study. Slight to moderate or
moderate transient salivation was observed immediately after ad-
ministration of the test article in all high-dose group female animals,
occurring with frequencies from ﬁve to nine observations per animal
between days 6 and 14, in four of ﬁve high-dose group males, oc-
curring with frequencies from ﬁve to nine observations per animal
between days 5 and 13, and in one male in the 2500 mg/kg dose
group on days 8 and 13. These ﬁndings were regarded as inciden-
tal and without toxicological signiﬁcance because they were of low
degree, transient in occurrence, and of short duration (ceasing within
a fewminutes after administration of the test article) and there were
no other related ﬁndings. This presentation, occurring in only the
two highest dose groups, is consistent with an etiology due to a phys-
ical or chemical feature of the test article, such as taste, although
such properties of the test article were not assessed. Transient sal-
ivation is also historically observed in vehicle-treated animals. No
test article-related effects on body weight or food consumption
(Table 2) were observed during the study, and the mean weight,
weight gain, food consumption, and food eﬃciency were similar
between the control and treatment groups throughout the study.
No eye lesions were observed on ophthalmologic examination in
any animals before or after the treatment period.
No remarkable alterations were observed in hematologic or clin-
ical chemistry parameters. A small number of statistically signiﬁcant
differences between treated and control animals, observed among
sexes (Tables 3 and 4), were not considered to be test article-
related or toxicologically meaningful because of low magnitude,
single occurrence, no dose dependency, absence of related gross or
histopathological ﬁndings, and because all observations remained
within historical control ranges of the laboratory.
On gross pathological examination, pyelectasia was observed in
onemale of the 750mg/kg dose group and onemale and one female
of the 2500 mg/kg dose group. Renal paleness was observed in one
male of the 2500 mg/kg dose group. A smaller than normal pros-
tate was observed in one male (animal #2412) of the high-dose
group, and slight or moderate hydrometra (indicative of the estrous
cycle of the female animals) was observed in one to three females
Table 5
Summary of necropsy ﬁndings in the 14-day repeated oral toxicity study.
Organs Dose group (mg/kg bw/day)
Observations
Control 250 750 2500 5000
Male
No macroscopic ﬁndings 5/5 5/5 4/5 3/5 4/5
Kidneys: Pyelectasia 0/5 0/5 1/5 1/5 0/5
Pale 0/5 0/5 0/5 1/5 0/5
Prostate: Smaller than normal 0/5 0/5 0/5 0/5 1/5
Female
No macroscopic ﬁndings 4/5 2/5 5/5 3/5 3/5
Kidneys: Pyelectasia 0/5 0/5 0/5 1/5 0/5
Uterus: Hydrometria 1/5 3/5 0/5 2/5 2/5
Data represent the number of animals with observation/number of animals
observed.
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per group in the control group and all, except the 750 mg/kg, dose
groups (Table 5). The small prostate, which is seen occasionally in
untreated experimental rats, was considered to be an individual al-
teration unrelated to administration of the test-article. The renal
changes (pyelectasia and paleness) and hydrometra are species-
speciﬁc alterations that occur in untreated animals of this species
and strain andwere not considered to be test article-related. No other
gross pathological lesions were observed in any animals of the treat-
ment or control groups.
Absolute and relative organ weights were similar among animals
in the treatment and control groups, with the exception of a slight
but statistically signiﬁcant (P < 0.05) difference in the weight of the
liver relative to body weight in males of the high-dose group and
a slight but signiﬁcant (P < 0.05) increase in thymus weight
Table 7
Summary of histopathology ﬁndings in the 14-day repeated oral toxicity study.
Organs Dose group (mg/kg bw/day)
Observations
Control 250 750 2500 5000
Male
No microscopic ﬁndings 5/5 / / / 4/5
Kidneys: No microscopic ﬁndings 5/5 / 1/1 2/2 5/5
Subacute lymphocytic pyelitis 0/5 / 0/1 0/2 1/5
Urinary bladder: Subacute lymphocytic cystitis 0/5 / / / 1/5
Prostate: Subacute lymphocytic prostatitis 0/5 / / / 1/5
Female
No microscopic ﬁndings 3/5 / / / 5/5
Kidneys: No microscopic ﬁndings 5/5 / / 1/1 5/5
Uterus: Dilatation 2/5 / / / 0/5
Abbreviations: /, not examined.
Data represent the number of animals with observation/number of animals observed.
Table 8
Summary of mean body weight and mean food intake data in the 90-day repeated oral toxicity study.
Mean body weight (g) Initial (Day 0) Midway (Day 42) End (Day 89)
Male
Control (N = 10) 295.2 ± 13.57 446.9 ± 34.04 505.3 ± 36.02
100 mg/kg bw/day (N = 10) 293.4 ± 15.22 429.4 ± 55.08 479.0 ± 79.16
300 mg/kg bw/day (N = 10) 292.9 ± 11.35 437.7 ± 34.62 497.5 ± 38.81
450 mg/kg bw/day (N = 10) 290.5 ± 11.54 424.8 ± 35.55 481.3 ± 51.75
600 mg/kg bw/day (N = 10) 291.1 ± 11.25 450.1 ± 38.58 510.0 ± 59.13
Female
Control (N = 10) 194.3 ± 11.91 255.4 ± 25.95 274.6 ± 29.79
100 mg/kg bw/day (N = 10) 193.0 ± 13.86 254.5 ± 21.27 268.7 ± 24.52
300 mg/kg bw/day (N = 10) 191.5 ± 8.68 260.1 ± 17.79 276.3 ± 23.22
450 mg/kg bw/day (N = 10) 191.8 ± 9.22 259.5 ± 22.09 277.6 ± 26.05
600 mg/kg bw/day (N = 10) 193.2 ± 11.16 261.6 ± 22.17 277.5 ± 28.00
Mean food consumption (g/rat/day) Week 1 (Days 0–7) Week 6 (Days 35–42) Week 13 (Days 84–89)
Male
Control (N = 10) 31.2 ± 2.51 30.1 ± 3.20 26.1 ± 2.07
100 mg/kg bw/day (N = 10) (% Deviation from control) 28.7 ± 2.65 (−8)* 28.2 ± 3.89 (−6) 23.6 ± 8.33 (−10)
300 mg/kg bw/day (N = 10) (% Deviation from control) 28.2 ± 3.21 (−9)* 29.8 ± 3.35 (−1) 28.1 ± 2.38 (8)
450 mg/kg bw/day (N = 10) (% Deviation from control) 27.4 ± 3.12 (−12)** 28.2 ± 2.65 (−6) 25.9 ± 3.18 (−1)
600 mg/kg bw/day (N = 10) (% Deviation from control) 27.4 ± 1.75 (−12)** 29.6 ± 3.16 (−2) 26.0 ± 2.58 (0)
Female
Control (N = 10) 20.9 ± 2.15 20.5 ± 1.92 18.3 ± 3.08
100 mg/kg bw/day (N = 10) (% Deviation from control) 19.8 ± 2.01 (−6) 20.2 ± 1.85 (−1) 17.8 ± 2.03 (−3)
300 mg/kg bw/day (N = 10) (% Deviation from control) 19.8 ± 1.55 (−5) 21.7 ± 1.56 (6) 19.0 ± 2.19 (4)
450 mg/kg bw/day (N = 10) (% Deviation from control) 19.5 ± 2.23 (−7) 21.2 ± 2.13 (3) 19.0 ± 2.42 (4)
600 mg/kg bw/day (N = 10) (% Deviation from control) 18.7 ± 1.59 (−11) 20.2 ± 1.95 (−1) 16.8 ± 1.79 (−8)
Mean body weight data represent the mean and the standard deviation at the beginning, mid-way through and end of the study.
Food intake data represent the mean value per rat per day and percent deviation from control at the beginning, mid-way through, and end of the study.
*P < 0.05 and **P < 0.01.
Table 9
Summary of selected ﬁnal hematological ﬁndings in female animals in the 90-day repeated oral toxicity study.
Dose (mg/kg bw/day) WBC (109/L) NEU (%) LYM (%) MONO (%) EOS (%) BASO (%)
Control (N = 10) 6.21 ± 1.54 11.91 ± 4.13 83.68 ± 4.27 2.36 ± 0.81 2.04 ± 0.95 0.01 ± 0.03
100 (N = 10) 6.22 ± 1.73 19.52 ± 10.49* 75.04 ± 10.85 2.92 ± 0.81 2.47 ± 0.54 0.05 ± 0.08
300 (N = 10) 5.54 ± 2.14 16.70 ± 5.33 78.31 ± 6.36 2.96 ± 1.76 2.02 ± 0.82 0.01 ± 0.03
450 (N = 10) 5.45 ± 1.57 16.27 ± 5.95 79.08 ± 7.85 2.37 ± 1.31 2.21 ± 1.13 0.07 ± 0.12
600 (N = 10) 5.21 ± 1.56 19.75 ± 6.50* 75.99 ± 7.38 2.32 ± 0.95 1.94 ± 0.61 0.00 ± 0.00
Abbreviations: Hb, hemoglobin; HTC, hematocrit; RBC, red blood cell; WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; MONO, monocyte; EOS, eosinophil; BASO,
basophil.
Data represent the mean values and the standard deviation.
* P < 0.05.
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Table 10
Summary of clinical chemistry in the 90-day repeated oral toxicity study.
Group (N = 10)
(mg/kg bw/day)
ALT (U/L) AST (U/L) GGT (U/L) ALP (U/L) Bilirubin
(μmol/L)
Creatinine
(μmol/L)
Urea
(mmol/L)
Glucose
(mmol/L)
Cholesterol
(mmol/L)
Male
Control 62.65 ± 16.61 105.62 ± 15.45 0.68 ± 0.39 80.30 ± 11.59 2.85 ± 0.36 26.44 ± 3.95 6.64 ± 0.78 6.42 ± 0.32 2.30 ± 0.51
100 60.89 ± 15.55 113.32 ± 24.79 0.84 ± 0.65 118.90 ± 91.51 2.74 ± 0.82 26.58 ± 4.04 7.86 ± 0.95** 6.30 ± 0.94 2.19 ± 0.27
300 67.91 ± 14.53 115.60 ± 21.61 0.81 ± 0.56 91.10 ± 17.80 2.69 ± 0.50 24.91 ± 2.93 7.44 ± 0.91 7.21 ± 0.59** 2.48 ± 0.80
450 62.13 ± 11.66 108.86 ± 11.28 0.55 ± 0.28 78.30 ± 18.64 2.70 ± 0.60 27.13 ± 2.81 7.39 ± 0.69 7.60 ± 0.88** 2.46 ± 0.44
600 52.68 ± 11.77 101.03 ± 11.44 0.89 ± 0.39 75.40 ± 14.55 2.75 ± 0.33 27.20 ± 3.81 6.56 ± 0.90 6.39 ± 0.68 2.32 ± 0.43
Female
Control 55.52 ± 16.48 121.21 ± 34.44 0.46 ± 0.30 53.50 ± 12.91 2.68 ± 0.45 29.98 ± 4.90 7.15 ± 1.52 5.61 ± 0.71 2.23 ± 0.44
100 55.32 ± 19.10 116.73 ± 42.26 1.54 ± 0.94** 53.00 ± 7.13 2.73 ± 0.63 28.65 ± 3.84 7.18 ± 0.97 5.62 ± 1.04 2.23 ± 0.61
300 72.34 ± 41.08 126.42 ± 40.12 0.98 ± 0.39** 86.70 ± 23.29** 2.78 ± 0.50 28.26 ± 2.98 7.33 ± 1.03 6.29 ± 1.21 2.10 ± 0.35
450 77.06 ± 68.05 118.06 ± 45.05 1.00 ± 0.96 83.80 ± 24.39** 2.78 ± 0.32 26.56 ± 3.37 6.82 ± 1.11 6.15 ± 1.11 2.37 ± 0.39
600 105.35 ± 159.83 156.48 ± 174.89 1.44 ± 1.51** 51.50 ± 10.96 2.77 ± 0.81 30.77 ± 2.35 6.30 ± 1.09 5.63 ± 1.29 2.00 ± 0.33
Group (N = 10)
(mg/kg bw/day)
Bile acids
(μmol/L)
Phosphate
(mmol/L)
Calcium
(mmol/L)
Sodium
(mmol/L)
Potassium
(mmol/L)
Chloride
(mmol/L)
Protein (g/L) Albumin
(g/L)
A/G Ratio
Male
Control 65.14 ± 26.73 2.05 ± 0.13 2.60 ± 0.14 140.70 ± 2.41 4.33 ± 0.22 102.95 ± 1.83 59.66 ± 3.53 31.86 ± 1.66 1.17 ± 0.13
100 60.31 ± 24.76 2.15 ± 0.29 2.61 ± 0.25 140.80 ± 2.49 4.41 ± 0.41 102.80 ± 2.55 60.37 ± 3.30 31.85 ± 2.33 1.12 ± 0.11
300 59.10 ± 14.18 2.15 ± 0.29 2.75 ± 0.07* 141.10 ± 1.37 4.28 ± 0.25 103.15 ± 1.46 62.41 ± 2.24 33.53 ± 0.74** 1.17 ± 0.09
450 56.57 ± 23.33 2.36 ± 0.26 2.82 ± 0.17** 139.10 ± 2.13 4.36 ± 0.12 102.09 ± 1.26 63.87 ± 5.28* 32.64 ± 1.49 1.07 ± 0.19
600 40.81 ± 19.81 2.16 ± 0.28 2.73 ± 0.09 141.40 ± 1.07 4.27 ± 0.25 103.52 ± 0.97 64.01 ± 2.63* 33.50 ± 0.97* 1.12 ± 0.09
Female
Control 56.25 ± 50.29 1.70 ± 0.23 2.65 ± 0.14 141.10 ± 1.85 3.87 ± 0.21 105.20 ± 2.07 60.12 ± 5.70 33.11 ± 2.72 1.24 ± 0.12
100 78.81 ± 49.51 1.60 ± 0.22 2.61 ± 0.08 141.50 ± 1.65 3.88 ± 0.30 104.47 ± 2.18 61.98 ± 3.21 34.16 ± 1.66 1.25 ± 0.18
300 45.02 ± 26.15 1.74 ± 0.25 2.70 ± 0.12 142.30 ± 1.83 3.89 ± 0.27 105.53 ± 1.57 63.60 ± 3.16 34.83 ± 1.50 1.22 ± 0.06
450 45.85 ± 14.34 1.88 ± 0.40 2.62 ± 0.18 142.40 ± 1.71 3.94 ± 0.24 105.93 ± 1.68 64.10 ± 4.08 34.69 ± 1.75 1.19 ± 0.16
600 62.97 ± 63.69 1.63 ± 0.33 2.66 ± 0.07 141.60 ± 0.70 3.81 ± 0.23 105.53 ± 1.37 62.07 ± 3.77 34.57 ± 1.66 1.26 ± 0.10
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; A/G, albumin to globulin ratio.
Data represent the mean values and the standard deviation.
*P < 0.05 and **P < 0.01.
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relative to brain weight in females of the low-dose group (Table 6).
Due to the lack of a dose-related effect, the small magnitude of the
differences, and the lack of gross or histopathological lesions, these
changes were considered to be without toxicological relevance and
unrelated to test article administration.
Histopathological examination (Table 7) revealed the presence
of moderate subacute lymphocytic pyelitis, cystitis, and prostati-
tis in a single male animal (#2412) of the high-dose group. These
observations were considered indicative of lymphocytic inﬂamma-
tion and were related to observations in this same animal of slightly
(marginal to the historical range) increased neutrophil percentage
(27.7 vs. 27.1%) and urea (11.93 vs. 11.75 mmol/L) compared to his-
torical control ranges. The collective ﬁndings in animal #2412 were
considered to be of no toxicological signiﬁcance and unrelated to
test article administration due to their occurrence as an individu-
al disorder. This conclusion was supported, retrospectively, by the
absence of similar ﬁndings in any animals of the 90-day study, herein
also reported. Dilatation of uterine horns, indicating estrus phase
of the sexual cycle and without associated pathological lesions, was
observed in two of ﬁve females of the control group. No other his-
topathological lesions were observed in any organs or tissues of any
animals in the control or high-dose groups. No histopathological
ﬁndings were observed in the kidneys of a small number of animals
in the middle dose groups where there were gross observations of
species-speciﬁc alterations.
No signs of toxicity that were considered related to administra-
tion of Zembrin® by gavage were observed in male or female
Crl:(WI)BR Wistar rats at doses of 250, 750, 2500, or 5000 mg/kg
bw/day for 14 consecutive days. The NOAEL was determined to be
5000 mg/kg bw/day.
3.2. Ninety-day repeated-dose oral toxicity study in rats
Nomortality was observed at any of the tested dose levels during
the 90-day treatment period. The animals exhibited normal behav-
ior and physical conditionwith no signiﬁcant abnormalities in clinical
signs observed throughout the study with one exception. During
the ﬁnal 2 weeks of the study, one male (animal #15) of the low
dose group exhibited slightly decreased activity and slight dyspnea
on days 74–77; moderately decreased activity, moderate dyspnea,
and moderate piloerection on days 87–89; and slightly sanguine-
ous nasal oriﬁces on days 87 and 88. Because these observations
were limited to only one animal in the low dose group, the ob-
served signs were not considered to be of toxicological concern.
No differences in behavior, sensory reactions to various types of
stimuli, grip strength, or locomotor activity between treated animals
and controls were observed during the functional observation battery.
Observations of reduced righting reﬂex occurred with similar in-
cidence in animals of all dose groups when compared to the control
groups (greatest incidences occurred in the control groups). There
were no signiﬁcant differences in the ActiMot light-beam frame
systemmeasured parameters of spontaneous locomotor activity (lo-
comotion, activity, spatial parameters, turning behavior, and rearing
behavior) between the test article dose groups and control groups.
No test article-related effects on body weight or food consump-
tion were observed during the study (see Table 8). A few statistically
signiﬁcant transient ﬂuctuations in mean body weight gain ob-
served among the sexes and dose groups were of low degree and
not dose-dependent. Mean food consumption was slightly, but sta-
tistically signiﬁcantly, lower in all treatedmale dose groups compared
to controls during the ﬁrst week of the study. The difference was
transient and of lowmagnitude, unrelated to body weight or weight
gain, and remained within the historical ranges of the laboratory.
Therefore the ﬁnding was not considered to be of toxicological rel-
evance. No eye lesions were observed on ophthalmologic
examination in any animals before or after the treatment period.
Statistically signiﬁcant elevations in white blood cell count, re-
ticulocyte count, and percentage of neutrophils together with a
statistically signiﬁcant decrease in percentage of lymphocytes were
observed in a single male (animal #15) of the 100 mg/kg bw/day
group (isolated clinical observations (reported above) and iso-
lated gross pathological ﬁndings were observed in the same animal)
and were considered indicative of an individual lesion unrelated to
the test article. No other remarkable alterations were observed in
hematologic or clinical chemistry parameters; however, slight but
statistically signiﬁcant differences in neutrophil percent (between
females of the 100 and 600mg/kg bw/day groups and controls) and
various clinical chemistry parameters (between male and female
animals of all dose groups and controls) were observed (Tables 9
and 10), but were not considered to be test article-related or tox-
icologically meaningful because of low magnitude, lack of dose-
relationship, and absence of related pathological ﬁndings and because
all observations remained within or marginal to historical control
ranges of the laboratory.
On gross examination, a blood ﬁlled thoracic formation was ob-
served in one male (animal #15) of the low-dose group. Together
with the white blood cell abnormalities and clinical observations
observed in this animal, the ﬁnding is consistent with gavage irri-
tation and, therefore, was not considered toxicologically relevant.
Several other sporadic lesions were observed in male animals of the
control group and all but the high-dose group of the treated animals
on gross pathological examination (Table 11). These lesions were
isolated to individual animals, were not dose related, and are
common ﬁndings in untreated rats and were, therefore, not con-
sidered to be of toxicological concern or test article-related.
Hydrometra, related to the sexual cycle and of no toxicological rel-
evance, was observed in some females of the control group and all
but the low dose group of treated animals (Table 11).
The liver to body weight ratio of high dose males was slightly
less compared to control males, and statistically signiﬁcant differ-
ences in mean adrenal weight and adrenal to body weight ratio and
mean heart to bodyweight ratio were observed in high-dose females
Table 11
Summary of necropsy ﬁndings in the 90-day repeated oral toxicity study.
Organs Dose group (mg/kg bw/day)
Observations
Control 100 300 450 600
Male
No macroscopic ﬁndings 9/10 9/10 9/10 9/10 10/10
Testes: Smaller than normal – bilateral 1/10 0/10 0/10 0/10 0/10
Thoracic cavity: Blood ﬁlled formation 0/10 1/10 0/10 0/10 0/10
Kidneys: Pyelectasia – unilateral 0/10 0/10 1/10 0/10 0/10
Cervical lymph nodes: Hemorrhagic inﬁltration 0/10 0/10 0/10 1/10 0/10
Female
No macroscopic ﬁndings 6/10 10/10 6/10 7/10 8/10
Uterus: Hydrometria 4/10 0/10 4/10 3/10 2/10
Data represent the number of animals with observation/number of animals observed.
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(Table 12). These differences were not considered to have biologi-
cal signiﬁcance, and no other differences in absolute or relative organ
weights were observed between control and treated animals.
Sporadic lesions upon histopathological examination (Table 13)
were revealed with similar frequency in the control and high-
dose group and were not considered treatment-related. Observed
lesions were alveolar emphysema, considered a consequence of ex-
sanguination; hyperplasia of bronchus associated lymphoid tissue,
a physiological phenomenon; alveolar histiocytosis, a common in-
cidental ﬁnding in older rats; and dilatation of the uterine horns,
indicating estrus phase of the sexual cycle. Sporadic lesions ob-
served in a single kidney of a 300mg/kg dose group male, a cervical
lymph node of a 450 mg/kg dose group male, and the testes of a
control groupmale were considered unrelated to the test article due
to the low frequency of their occurrence as isolated individual dis-
orders in animals of the control and lower dose groups only and
their common observation in untreated experimental rats of this
strain with similar age. No other microscopic lesions were ob-
served in any organs or tissues of control or treated animals subjected
to histopathological examination.
No signs of toxicity that were considered related to administra-
tion of Zembrin® by gavage were observed in male or female
Crl:(WI)BR Wistar rats at doses 100, 300, 450, and 600 mg/kg bw/
day for 90 consecutive days. The NOAEL was determined to be
600 mg/kg bw/day.
4. Discussion and conclusion
The present studies are the ﬁrst formal in vivo toxicological
studies of an extract of S. tortuosum (Zembrin®) and provide sup-
porting evidence for the safety and tolerability ﬁndings in the ﬁrst
clinical study (Nell et al., 2013). The repeated administration of
Zembrin® for 90 days by gavage to Wistar rats resulted in a NOAEL
of 600mg/kg bw/day. Applying a 100-fold uncertainty factor to com-
pensate for inter- and intraspecies differences, results can be
extrapolated to an acceptable daily intake of 420 mg by a 70 kg
human. Zembrin® is intended to be used as an ingredient in func-
tional foods, beverages, and dietary supplements. The recommended
consumption is 25mg per day. This is 0.357mg/kg bw/day in a 70 kg
adult, which is 1680 times less than the NOAEL of 600 mg/kg bw/
day. The indigenous classiﬁcation as a mak, or mild variety, of the
S. tortuosum variety selected for extraction of Zembrin® is sup-
ported by our ﬁndings that there were no changes in central nervous
system signs, behavior, activity, weight, or food intake at any of the
doses studied.
In previous safety assessments (Harvey, 2008, unpublished;
Jurkowski, 2008, unpublished), we observed that ≤100 μg/mL of
Zembrin® had no effect on several mammalian cell lines and did not
cause genotoxicity in vitro, as revealed by assays for induction of
micronuclei in CHO-K1 and V79 cells, or bacterial reversion in an
Ames test. At 10 μg/mL Zembrin® did partly reduce K+ currents
through hERG channels in whole cell patch clamp experiments al-
though this concentration is unlikely to be achieved in vivo.
A small series of clinical case studies of subjects who ingested
daily amounts of 50–100mg of uncharacterized milled S. tortuosum
raw material reported positive ﬁndings on mood and feelings of
anxiety (Gericke, 2001), and an in vivo study of an uncharacterized
extract of S. tortuosum in rats demonstrated a positive outcome on
the behavioral effects of restraint stress (Smith, 2011). Positive effects
onwell-being, including improved stress coping and improved sleep,
were noted in patient diaries by some participants taking extract
S. tortuosum (Zembrin®) in the ﬁrst clinical study of this extract (Nell
et al., 2013). A recent double-blind placebo-controlled cross-over
pharmaco-fMRI study of a single 25 mg dose administration of
Zembrin® in healthy university students demonstrated signiﬁcant
attenuation of amygdala reactivity to fearful faces under lowTa
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perceptual load conditions and reduced amygdala–hypothalamus
coupling (Terburg et al., 2013).
The above clinical and preclinical results support the sug-
gested potential of Zembrin® as beneﬁcial to promotion of a sense
of emotional well-being, calming effect, and stress relief. The present
in vivo toxicological studies on Zembrin®, together with the clini-
cal evidence of safety and tolerability (Nell et al., 2013) and our
unpublished in vitro safety studies, provide a foundation for future
studies designed to evaluate health-promoting applications of extract
S. tortuosum (Zembrin®) in functional foods, beverages, and dietary
supplements.
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Table 13
Summary of histopathology ﬁndings in the 90-day repeated oral toxicity study.
Organs Dose group (mg/kg bw/day)
Observations
Control 100 300 450 600
Male
Cervical lymph nodes: Hemorrhages 0/10 / / 1/1 0/10
Epididymides: Lack of mature spermatozoa 1/10 / / / 0/10
Kidneys: Pyelectasia – unilateral 0/10 / 1/1 / 0/10
Lungs: Alveolar emphysema 2/10 / / / 2/10
Alveolar histiocytosis 1/10 / / / 1/10
Hyperplasia of BALT 2/10 / / / 2/10
Testes: Decreased intensity of spermatogenesis 1/10 / / / 0/10
Female
Lungs: Alveolar emphysema 1/10 / / / 2/10
Alveolar histiocytosis 1/10 / / / 1/10
Hyperplasia of BALT 1/10 / / / 2/10
Uterus: Dilatation 4/10 / / / 2/10
Abbreviations: /, not examined; BALT, bronchus associated lymphoid tissue.
Data represent the number of animals with observation/number of animals observed.
Organs without lesions in 10/10 control or high-dose animals are not shown.
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